Eisai reports upbeat results from PhIII epilepsy study

Two years after dumping its research program for perampanel as a possible new therapy for Parkinson's, Eisai says that it has reaped positive Phase III data for the drug in epilepsy. Researchers say that E2007 reduced median seizure frequency while increasing the percentage of patients who experienced a big drop in seizure frequency.

Investigators said that they tracked a statistically significant response for patients taking both the 4 mg and 8 mg doses compared to placebo. Two more Phase III studies are also underway.

The global study--Study 306--was conducted primarily in Europe and Asia with 706 patients from 25 countries. Patients were randomized to placebo or one of three perampanel doses: 2 mg, 4 mg or 8 mg.

- check out the Eisai release

Suggested Articles

The deal comes almost two years after Roche dropped the tumor microenvironment modulator after putting it through a clutch of early-phase studies.

The buzzy life sciences company Verily is looking to speed up COVID testing with a new lab based at its native South San Francisco.

Although Genfit canned its NASH program last month, it has been plugging away at a blood-based diagnostic for the liver disease.